MXCT (MaxCyte) Owner Earnings per Share (TTM): -0.42 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MXCT MaxCyte Inc MXCT
61 GF Score
Price $1.08
GF Value $2.56
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MaxCyte Owner Earnings per Share (TTM)?

MaxCyte MXCT -3.57% 61 Owner Earnings per Share (TTM) is -0.42 as of Mar. 2026. GuruFocus rates MXCT with a GF Score™ of 61/100 and a GF Value™ of $2.56 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 308 Medical Devices & Instruments companies, MaxCyte ranks worse than 324675% on this metric.

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

MaxCyte's Owner Earnings per Share (TTM) ended in Mar. 2026 was $-0.42. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for MaxCyte's Owner Earnings per Share (TTM) or its related term are showing as below:



MXCT's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 24.71
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

MaxCyte's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.37. It's PE Ratio (TTM) ratio for today is At Loss.

MaxCyte's EPS without NRI for the three months ended in Mar. 2026 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.31. It's PE Ratio without NRI ratio for today is At Loss.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


MaxCyte Owner Earnings per Share (TTM) Related Terms


MaxCyte Owner Earnings per Share (TTM) Historical Data

* Premium members only.

The historical data trend for MaxCyte's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MaxCyte Owner Earnings per Share (TTM) Chart

MaxCyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -0.33 -0.36 -0.41 -0.49

MaxCyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.49 -0.52 -0.49 -0.42

MXCT vs RCEL, HYPR, CVRX: Owner Earnings per Share (TTM) Comparison

For the Medical Devices subindustry, MaxCyte's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MaxCyte Price-to-Owner-Earnings vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where MaxCyte's Price-to-Owner-Earnings falls into.


MXCT
61GF Score
MaxCyte Inc MXCT
Owner Earnings per Share (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MaxCyte Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

MaxCyte's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -39.12
Depreciation, Depletion and Amortization 5.27
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 5.62
Change In Working Capital -5.60
Shares Outstanding (Diluted Average) 106.88

1. Start with "Net Income" from income statement. MaxCyte's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-39.12 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. MaxCyte's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2026 was $5.27 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. MaxCyte's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $5.62 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

MaxCyte's 5-Year Average Maintenance Capital Expenditure = $5.62 Mil

5. "Change In Working Capital" is from cashflow statement. MaxCyte's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.60 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. MaxCyte's Shares Outstanding (Diluted Average) for the months ended in Mar. 2026 was 106.875 Mil.

MaxCyte's Onwer Earnings Per Share for Mar. 2026 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -39.119 +5.266+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-5.6242807337419+-5.602)/106.875
=-0.42

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=1.08/-0.42
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Owner Earnings per Share (TTM) of -0.42 mean?
MaxCyte (MXCT) has a Owner Earnings per Share (TTM) of -0.42 as of Mar. 2026. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on MaxCyte. According to the industry distribution chart, MaxCyte ranks #999999 out of 308 companies in the Medical Devices & Instruments industry.
Is MaxCyte's Owner Earnings per Share (TTM) too high?
MaxCyte's current Owner Earnings per Share (TTM) is -0.42. Based on the distribution chart, MaxCyte ranks #999999 out of 308 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MaxCyte has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Owner Earnings per Share (TTM) compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #999999 out of 308 companies for Owner Earnings per Share (TTM). This places MaxCyte in the lower half of its industry. The industry median Owner Earnings per Share (TTM) is 24.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Owner Earnings per Share (TTM) for a Medical Devices & Instruments company?
The median Owner Earnings per Share (TTM) among Medical Devices & Instruments companies is 24.71, based on 308 companies in the industry. Companies in the top quartile (top 25%) have a Owner Earnings per Share (TTM) significantly above this median, while those in the bottom quartile fall well below. However, Owner Earnings per Share (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Owner Earnings per Share (TTM) mean?
A high Owner Earnings per Share (TTM) can signal that a stock is expensive relative to its fundamentals. Warren Buffett defined owner earnings as reported earnings plus depreciation less average maintenance capital expenditure. View historical data on MaxCyte. For the Medical Devices & Instruments industry, the median Owner Earnings per Share (TTM) is 24.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Owner Earnings per Share (TTM) is -0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.56, compared to a current price of $1.08 — trading 57.8% below its estimated fair value. The current Owner Earnings per Share (TTM) is -0.42. MaxCyte's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Owner Earnings per Share (TTM) calculated?
Owner Earnings per Share (TTM) is calculated from a company's financial statements. For MaxCyte (MXCT), the current Owner Earnings per Share (TTM) is -0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MaxCyte (MXCT) Overvalued in 2026?

Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued. The current stock price of $1.08 is trading 57.8% below its estimated GF Value™ of $2.56. GuruFocus considers MaxCyte to be Possible Value Trap.

Key valuation signals for MXCT:

  • Owner Earnings per Share (TTM): -0.42
  • GF Value™: $2.56 vs. price of $1.08 (57.8% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MaxCyte Business Description

Other Exchanges MYE0:Germany
Address 9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
61GF Score

Get the complete analysis for MXCT

Owner Earnings per Share (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.08
Price
$2.56
GF Value